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ABSTRACT Hypopituitary Ames dwarf mice were
injected either with growth hormone (GH) or thyrox-
ine for a 6-wk period to see whether this intervention
would reverse their long life span or the resistance of
their cells to lethal stresses. Ames dwarf mice sur-
vived 987  24 d (median), longer than nonmutant
control mice (66448), but GH-injected dwarf mice
did not differ from controls (707  9). Fibroblast
cells from Ames dwarf mice were more resistant to
cadmium than cells from nonmutant controls (LD50
values of 9.981.7 and 3.90.8, respectively), but
GH injections into Ames dwarf mice restored the
normal level of cadmium resistance (LD505.80.9).
Similar restoration of normal resistance was ob-
served for fibroblasts exposed to paraquat, methyl
methanesulfonate, and rotenone (P<0.05 in each
case for contrast of GH-treated vs. untreated dwarf
mice; P<0.05 for dwarf vs. nonmutant control mice.)
T4 injections into Ames dwarf mice, in contrast, did
not restore normal life span. We conclude that the
remarkable life-span extension of Ames dwarf mice,
and the stress resistance of cells from these mice,
depends on low levels of GH exposure in juvenile
and very young adult mice.—Panici, J. A., Harper,
J. M., Miller, R. A., Bartke, A., Spong, A., Masternak,
M. M. Early life growth hormone treatment shortens
longevity and decreases cellular stress resistance in
long-lived mutant mice. FASEB J. 24, 5073–5079
(2010). www.fasebj.org
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Studies of aging in laboratory animals have indi-
cated that alteration of signaling pathways triggered by
growth hormone (GH), insulin, and insulin like growth
factor-1 (IGF-1) can have a major effect on life span and
aging in multiple species (1). In rodents, growth hor-
mone deficiency or resistance is known to be associated
with extended longevity of Snell dwarf, Ames dwarf,
and GHRKO mice (2–6). On the other hand, there is
some evidence to suggest that GH administration may
be beneficial to the health of elderly people (7),
although the literature on this point is equivocal (8–
10). Meta analysis by Liu et al. led them to conclude that
based on available evidence, GH cannot be recom-
mended for use for healthy elderly individuals (11).
Nonetheless, GH is widely advertised as an antiaging
treatment.
The present study employed Ames dwarf (df/df)
mice, which are GH deficient due to their homozygosity
for a recessive loss-of-function mutation at the Prop1
locus (Prop1df) and resultant failure of differentiation
of several lineages of anterior pituitary cells during fetal
development (4). Besides GH deficiency, this mutation
also leads to deficiency of prolactin (PRL) and thyroid-
stimulating hormone (TSH) production, with second-
ary suppression of circulating levels of insulin-like
growth factor-1 (IGF-1), thyroid hormones, insulin, and
glucose (4, 12–14). Ames dwarf mice live 50% longer
than their normal siblings (2, 4). This mutation not
only extends average and maximum longevity in these
animals, but also leads to better maintenance of cogni-
tive function (15), greater resistance to oxidative stress
(16), and decreased or delayed incidence of cancer
(17). Ames dwarf mice are characterized by increased
insulin sensitivity (13, 18, 19) along with decreased
levels of serum glucose and insulin. Improved insulin
signaling has been correlated with increased longevity,
while insulin resistance often predicts shorter life span
(19). Our previous studies with GH or GH/thyroxine
(T4) treatment in Ames dwarf mice indicated that
replacement of these hormones can negatively affect
insulin signaling pathways, causing insulin resistance
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and several alterations in insulin signaling pathways in
insulin target organs (20, 21).
In the present study we investigated the effects of
early life treatment with GH on mouse longevity and on
resistance of cultured dermal fibroblasts to different
environmental stressors in df/df mice. The results
indicate that a relatively brief period of GH treatment
during early stages of postnatal life can both shorten
life span and decrease the resistance of skin-derived cell
lines to stressful stimuli.
MATERIALS AND METHODS
Animals
Ames dwarfs (Prop1df), homozygous mice (df/df) were pro-
duced by mating heterozygous females and homozygous
mutant males in our breeding colony at Southern Illinois
University (SIU). In this colony, the Prop1df mutation is
maintained on a heterogeneous genetic background. All
animal protocols were approved by the Southern Illinois
University Laboratory Animal Care Committee. Animals were
maintained under temperature- and light-controlled condi-
tions (20–23°C, 12-h light-dark cycle).
Hormonal treatment
Growth hormone treatment and longevity
Once-daily injection. Groups of 15–17 Ames dwarf males were
subjected to treatment with porcine GH (pGH) via subcuta-
neous (s.c.) injection [4 g/g body weight (bw)/d], given
1/d starting at the age of 2 wk and continuing for 6 wk
(df/df-pGH treated). Once-daily saline-treated dwarfs (df/df)
of the same age were used as a control. After 6 wk of
treatment, animals were set aside for a longevity study, and
mice in these groups were not exposed to any other manip-
ulations except for recording of body weight.
Twice-daily injections. Groups of 9–10 Ames dwarf males
were subjected to treatment with bovine GH (bGH) via s.c.
injection (6 g/g bw/d), given 2/d starting at the age of 2
wk and continuing for 6 wk (df/df-bGH treated). On Satur-
days and Sundays, animals were injected only once with a full
dosage following a previous protocol (21). Untreated df/df
and wild-type (WT) littermates of the same age were used as
a control. After 6 wk of treatment, some animals were set
aside for a longevity study, and mice in these groups were not
exposed to any other manipulations except for recording of
body weight.
Separate groups of animals produced using the same
protocol were evaluated for glucose tolerance at 2 time
points: 1 d after last injection and 1 mo after last injection,
using a previously published protocol (21).
Thyroxine treatment and longevity
Female and male Ames dwarf mice were treated with T4
(l-thyroxine; Sigma, St. Louis, MO, USA) in 0.9% saline
solution at pH 7.8 by s.c. injection (0.1 g/g bw; 0.7 g/50 l
dose) 3/wk (Monday, Wednesday, Friday), following a
previously published protocol (20). Control Ames dwarfs
were injected with 0.9% saline according to the same sched-
ule. Each group consisted of 10 or 11 mice. All treatments
were started at the age of 2 wk and continued for 6 wk. At the
age of 8 wk, the treatment was stopped, and longevity was
monitored.
Growth hormone treatment and fibroblast stress resistance
Groups of 12–14 Ames dwarf males were given 2/d s.c.
injections of pGH (6 g/g bw/d; Alpharma, Bridgewater, NJ,
USA), starting at the age of 2 wk and continuing for 6 wk
(df/df-pGH treated). On Saturdays and Sundays animals,
were injected only 1, with a full daily dosage (6 g/g bw/d).
Untreated df/df and normal (N) littermates of the same age
were used as controls. After 6 wk of GH treatment, the
animals were deprived of food overnight; a serum sample was
taken for blood glucose determination, and mice were then
euthanized (21). Tails were collected, surface-sterilized using
70% ethanol, placed in sterile culture medium, and shipped
by overnight courier to Michigan for establishment of cell
cultures.
Fibroblast stress study
Primary cultures of dermal fibroblasts were derived from each
tail snip using an established protocol (22–24). In brief, on
arrival biopsies were further washed in 70% ethanol, placed
in Dulbecco’s modified Eagle medium (DMEM, high-glucose
variant), diced to 0.5 mm, and digested overnight with
collagenase type II (1000 U total/biopsy) dissolved in DMEM
supplemented with 10% heat-inactivated fetal bovine serum,
antibiotics (100 U/ml penicillin and 100 g/ml streptomy-
cin), and 0.25 g/ml of fungizone at 37° in a humidified
incubator with 5% CO2 in air. After collagenase treatment,
cells were dislodged, passed through sterilized nylon netting,
and centrifuged for 5 min at 200 g to pellet the cells. After
centrifugation the cells were resuspended in DMEM with 20%
heat-inactivated fetal bovine serum, antibiotics and fungizone
as indicated previously. Approximately 2.5  105 cells in 5 ml
medium were seeded into tissue culture flasks of 25 cm2
surface area. Cell cultures were then fed at d 3 (replacing
two-thirds of the medium), and subcultured at d 7 at a density
of 7.5  105 in tissue culture flasks of 75 cm2 surface area to
produce passage 1 cultures. Subsequent passages were split at
6-d intervals, with 2/3 total volume of media removed at d
3 and replaced with fresh DMEM with 20% heat-inactivated
fetal bovine serum with antibiotics and fungizone. At the end
of the third passage (6 d after seeding), confluent cells were
harvested for assessment of stress resistance as described
previously (22–24). In brief, cells were counted by hemocy-
tometer, diluted to a concentration of 3  105/ml in DMEM
with 10% fetal bovine serum with antibiotics and fungizone,
and seeded into a 96-well tissue culture-treated microtiter
plate at a volume of 100 l/well. The next day, the medium
was removed and replaced by serum-free DMEM supple-
mented with 2% bovine serum albumin, antibiotics, and
fungizone for 24 h, followed by exposure to the cytotoxic
stressors over a range of doses. For UV light testing, cells were
washed, then irradiated with UV light (254 nm at 5.625
J/m2/s) in 100 l of Dulbecco’s PBS. Survival was measured
18 h later by a test based on reductive cleavage of the
tetrazolium dye WST-1 using the manufacturer’s protocol.
The LD50, i.e., dose of stress agent needed to kill 50% of the
cells, was then estimated for each cell line for each stress.
Statistics
The effect of GH treatment on fibroblast stress resistance was
evaluated, based on LD50 estimates, using 1-way ANOVA
followed by a Tukey-Kramer post hoc test in instances where
the ANOVA calculation indicated a significant difference
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among treatment groups. In cases where the normality as-
sumption was violated, data were log transformed prior to
analysis. Differences in mouse survival were evaluated using
the log-rank test.
RESULTS
Hormonal treatment and longevity
Once-daily GH treatment with the dosage of 4 g/g
bw/d starting at 2 wk of age and continuing for 6 wk did
not alter the longevity of Ames dwarf mice (Supplemen-
tal Fig. 1). In contrast, GH administered 2/d to df/df
mice between 2 and 8 wk of age at a higher dose of 6
g/g bw/d significantly shortened their life span rela-
tive to untreated df-df mice (log-rank test, P0.0005)
(Fig. 1). The longevity of these GH-treated df/df mice
was indistinguishable from the life span of the WT
littermate controls.
As expected, GH treatment caused significant so-
matic growth of df/df mice in comparison to their
untreated littermates (P  0.001); however, the GH-
treated dwarf mice did not reach the same body weight
as the WT controls (Fig. 2).
A glucose tolerance test (GTT) performed 1 d after
the last injection of GH indicated that GH treatment
resulted in significant impairment of glucose tolerance
in df/df-bGH mice in comparison to df/df mice
(P0.01) (Fig. 3A). This effect was transient, in that
glucose tolerance was no longer different between
bGH-treated df/df and untreated df/df mice 1 mo after
the cessation of the treatment (Fig. 3B).
T4 levels are also severely reduced in df/df mice.
Injections of T4 between 2 and 8 wk of age did not
significantly alter longevity of either males or females
(P0.3 and P0.5, respectively) (Fig. 4), although
body weight was increased by this treatment in both
sexes (P0.0001 for both) (Fig. 5).
Growth hormone treatment and fibroblast stress
resistance
Effective responses and protection from negative ef-
fects of environmental and cellular stressors may play
an important role in determining longevity and in
protection from age-related diseases. As expected from
previous studies in Ames dwarf mice and in phenotyp-
ically similar Snell dwarf mice (22–24), dermal fibro-
blasts derived from untreated Ames dwarf mice were
significantly more resistant than cells from littermate
controls to the lethal effects of cadmium, paraquat, and
MMS as well as resistant to rotenone-induced inhibition
of the plasma membrane redox system (PMRS) (25,
26), as shown in Fig. 6. For each of these agents,
resistance is significantly higher in cells from untreated
df/df mice than in cells from littermate controls, as
evaluated by 1-way ANOVA followed by the Tukey-
Kramer post hoc test (P0.04 for all). Cells from Ames
dwarf mice were also better able to tolerate low glucose
culture conditions in comparison to cells derived from
WT mice, although this difference was only marginally
significant by ANOVA (P0.06) (Fig. 6). Although a
previous study had found increased resistance of Ames-
derived fibroblasts to hydrogen peroxide and UV irra-
diation (24), in the current group of mice we found no
significant difference between dwarf and controls in
resistance to these two agents (data not shown).
Cells from dwarf mice that had been exposed to 6 wk
of GH treatment resembled cells derived from normal
control mice in their lower resistance to MMS, para-
quat, and cadmium toxicity, as well as their tolerance to
low glucose culture conditions (P0.05 for all) (Fig. 6).
Resistance of cells from GH-treated dwarf mice to
rotenone-induced inhibition of PMRS activity was not
Figure 2. Body weight of Ames dwarf and control WT male
mice subjected to 6 wk of GH treatment. Ames dwarf (df)
mice were exposed between 2 and 8 wk of age (as indicated)
with bGH (df/df-bGH treated, n 22). Untreated WT (n9)
and df/df (n17) were used as controls. Time points repre-
sent mean  se weight of each group.
Figure 1. Kaplan–Meier survival plot of Ames dwarf mice
treated with bGH [dwarf (GH)], untreated WT controls, and
untreated Ames dwarf mice [dwarf (saline)] (n9–10). All
mice were males treated 2/d for 6 wk starting at age 2 wk via
s.c. injection (6 g/g bw/d).
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significantly different either from untreated dwarfs or
untreated controls (Fig. 6).
DISCUSSION
In this study we investigated separately the effects of
GH and T4 on longevity in Ames dwarf mice, which are
characterized by deficiency of these hormones. We
have consistently observed that Ames dwarf mice live
longer than their WT controls, but it is still controver-
sial as to whether GH deficiency is the cause of ex-
tended longevity in these animals (27). Indeed, the
concomitant lack of GH, TSH, and PRL does raise the
possibility that hormonal imbalances other than, or in
conjunction with, GH deficiency could be important
mediators of life span regulation in these animals. The
extended longevity of mice that lack the GH recep-
tor/GH binding protein (GHRKO mice), which dis-
rupted GH signaling with apparently normal TSH and
increased or normal PRL levels (5, 6) suggests that
altered GH/IGF levels may be a major factor in the
longevity of Ames and Snell dwarf mice. The longevity
of PAPP-A-knockout mice, which carry a deletion of a
protease that cleaves IGF-1 binding proteins and thus
could modulate levels of IGF-1 in multiple tissues, also
provides indirect support for a conclusion that dimin-
ished GH and/or IGF-1 signals play a major role in the
longevity of Ames dwarf mice (28).
We have previously reported that skin-derived cells
from Ames, Snell, and GHRKO mice retain resistance
to multiple forms of lethal stress through many rounds
of in vitro mitosis and cellular proliferation, consistent
with epigenetic control mechanisms induced in vivo
and maintained in extended culture (22–24). The
stress resistance is not present in cells taken from
newborn Snell dwarf mice, but arises in the first few
months of postnatal life, presumably as a response to
differences between dwarf and control mice in circulat-
ing hormone levels during early postnatal life (23). Cell
lines derived from mice 4–5 d of age show no genotypic
effect on resistance to UV irradiation or cadmium
toxicity and only a small difference in H2O2 resistance,
but cells derived from young adult dwarf mice (3–4 mo
old) were significantly more resistant to each of these
stressors compared to cells from control mice. Snell
dwarf and control mice are the same size at birth,
reflecting exposure to their shared intrauterine envi-
ronment, but show different growth trajectories in the
first few weeks after birth as they become dependent on
their own intrinsic, and distinct, hormonal levels.
Our new data are also consistent with the idea that
both longevity and patterns of cellular stress resistance
can be influenced by GH and/or IGF-1 signals in the
first 2 mo of life. We subjected GH-deficient Ames
dwarf mice to GH during early postnatal development,
a period during which GH is critical for growth and for
development of physiological organs. Since the average
Figure 4. Kaplan–Meier survival plot of male and female
Ames dwarf mice treated with T4 or saline (n10–11). All
mice were treated for 6 wk at the age of 2–8 wk.
Figure 3. Results of GTTs in GH-treated Ames dwarf (df/df-bGH treated) and untreated WT and df/df mice. All groups were
deprived of food overnight. In the morning, mice were injected i.p. with glucose (2 g/kg bw). Glucose was measured in samples
collected from the tail vein at specified time points. Values are means  se. A) GTT 1 d after last GH injection. B) GTT 1 mo
after last GH injection.
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life span of df/df mice is32 mo, the 6 wk of treatment
represents 5% of the expected life span. The weight
trajectory of 2/d GH-injected dwarf mice was inter-
mediate between that of untreated dwarfs and un-
treated controls, suggesting that the levels of GH and
IGF-1 produced in these mice did not fully reconstitute
the hormonal levels needed for normal growth regard-
less of increased dosage in 2/d-treated mice. In
addition, in our previous study using the same protocol,
we have shown that 6 g/g bw/d dosage of GH does
elevate circulating IGF-1 but does not normalize it in
df/df mice (21). Nonetheless, providing GH by 2/d
injection during this period shortened the life span of
df/df mice to match that of WT animals. This intrigu-
ing finding strongly suggests that deficiency of GH in
df/df mice during development is important for their
exceptional longevity and that diminished levels of GH
signal during early development are critical to the
longevity of these animals. Notably, thyroxine supple-
mentation administered during the same postnatal
period had no effect on life span.
As expected, body weight significantly increased in
bGH-treated df/df mice. The lack of complete normal-
ization of body weight in these animals suggests that the
animals were not exposed to potentially harmful over-
doses of GH. It is possible that more frequent injections
or higher doses of GH might allow df/df mice to attain
a growth rate characteristic of control mice, although
our data do not rule out the idea that normal growth
trajectories might require normal levels of both GH
and thyroid hormones. It was shown in pervious exper-
iments that GH treatment suppresses insulin sensitivity
and negatively alters insulin signaling in df/df mice
(21). In the current study, we showed that GH treat-
ment causes glucose intolerance in df/df mice, but that
this effect seems to be transient and partly reversible
within 4–6 wk after discontinuation of the GH injec-
tion regimen. Similar alterations in glucose tolerance
Figure 5. Body weight of male and female Ames dwarf mice subjected to 6 wk of treatment with T4 or saline (n10–11) during
the period indicated on the graph. Time points represent means  se.
Figure 6. Stress resistance in skin-
derived fibroblasts from dwarf mice
treated with pGH, untreated WT
controls, and df/df male mice. Sym-
bols represent individual mice of the
indicated genotype; horizontal rule
indicates mean value in each case;
n11–4. a,bValues that do not share
a superscript letter are statistically
significant (P0.05).
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were observed when healthy elderly humans were
treated with human recombinant GH (hrGH) (8).
As noted, treating Ames dwarf mice with thyroxine,
another hormone dramatically reduced in df/df mice,
did not alter the longevity of either males or females,
although it significantly increased body weight in both
genders.
Several studies (22, 24, 29, 30) have suggested that
fibroblasts from long-lived species of mammals are
resistant to many kinds of stress in vitro, though there
are exceptions to this pattern, too. It is not yet known
whether the cellular mechanisms that lead to stress
resistance in cells from long-lived species are similar to
those that lead to stress resistance in cells from Snell,
Ames, and GHRKO mice. Our current data show that
GH treatment sufficient to restore normal (i.e., re-
duced) life span in Ames dwarf mice also led to a
reversal of the resistance of skin-derived cells to cad-
mium, paraquat, MMS, and low glucose, producing a
set of cellular traits normally seen in cells from WT
mice. Moreover, this decline in stress resistance could
be demonstrated, in vitro, long after the cessation of
exposure to different levels of GH in vivo, in that the
cells from dwarf and GH-treated dwarf mice had been
expanded for several weeks in parallel and under
identical culture conditions prior to stress testing. Our
results suggest that cellular resistance to damage caused
by endogenous or environmental stresses could con-
tribute to the longevity of df/df mice, although this
model depends on the untested assumption that other
cell types in these mice also exhibit some of the stress
resistance properties documented in skin-derived cul-
tured fibroblasts.
Our present results were somewhat unexpected, be-
cause Vergara et al. (31) had previously seen no effect
of early life GH treatment on longevity of Snell dwarf
mice. Our protocol differed from that of Vergara et al.
(31) in a number of potentially influential details. For
example, in the Vergara study with Snell dwarfs, GH
was administered only 1/d. Furthermore, the dosages
were administered on a per-animal rather than per-unit
body weight basis, and thus were effectively declining,
from 8 to 3–4 g/g, as the animals grew during the
study. Lastly, in the Vergara protocol, GH injections
were started at the age of 4 wk (rather than at 2 wk as
in the current experiments) and continued up to 15 wk
of age. The earlier starting age, adjustments of dose to
body weight, and higher frequency of injections in the
current protocol may well have accounted for the
positive result seen in our study but not in the prior
work on aging rate and eventual longevity of Snell
dwarf mice. The use of 2/d injections may be espe-
cially critical for studies of male mice. It is known that
in males GH is released in a pulsatile fashion into the
circulation, and thus injecting mice 2/d may more
closely approximate the physiological pattern of GH
release. Differences in background genes may also
complicate comparison of the two studies; the Ames
control stock differs in many ways from the (DW/J x
C3H/HeJ)F1 mice used by Vergara et al. (31), and has
a substantially shorter life expectancy. Clarification of
these ideas would require additional experiments com-
paring a range of hormonal interventions on several
background stocks.
Lifelong exposure to T4 (a protocol we did not
explore in the current study) led to partial reduction of
the life span of Snell dwarf mice in the Vergara et al.
(31) experiments. In contrast, short-term (6 wk) expo-
sure to T4 in our experiments had no significant effect
on longevity. It seems plausible that long-term and
short-term T4 treatment could well have different ef-
fects on health and life span; documentation that the
lifelong protocol avoided hyperthyroid toxicity would
help to clarify the basis for the effects seen. In any case,
our results imply that transient, early life exposure to
GH is more potent than similar treatment with T4 in its
effect on longevity in the Ames dwarf mice.
In summary, the present results indicate that tran-
sient GH treatment early in life can shorten longevity
and decrease cellular stress resistance in Ames dwarf
mice. The same treatment was previously shown to be
detrimental for insulin signaling in df/df mice. We also
found that combining identical 2/d GH treatment
with parallel T4 treatment does not normalize the
growth of Ames dwarf mice (20, 21). More work will be
needed to confirm these findings on other back-
grounds and for other dwarfing alleles to identify the
critical “time window” for the observed effects of GH,
and to elucidate the mechanism of GH actions on aging
and longevity. Our data strongly imply, however, that
the levels of GH and/or IGF-1 early in adult life could
be a key determinant of longevity and aging rate, and
that normal levels of GH signaling during this time
reduce mouse life span, presumably by a long-lasting
effect on risks of multiple forms of lethal, late-life
illness.
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